Stock Research for ACST

ACST

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACST Stock Chart & Research Data

The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACST Due diligence Resources & Stock Charts

The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACST Detailed Price Forecast - CNN Money CNN View ACST Detailed Summary - Google Finance
Yahoo View ACST Detailed Summary - Yahoo! Finance Zacks View ACST Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACST Trends & Analysis - Trade-Ideas Barrons View ACST Major Holders - Barrons
NASDAQ View ACST Call Transcripts - NASDAQ Seeking View ACST Breaking News & Analysis - Seeking Alpha
Spotlight View ACST Annual Report - CompanySpotlight.com OTC Report View ACST OTC Short Report - OTCShortReport.com
TradeKing View ACST Fundamentals - TradeKing Charts View ACST SEC Filings - Bar Chart
WSJ View Historical Prices for ACST - The WSJ Morningstar View Performance/Total Return for ACST - Morningstar
MarketWatch View the Analyst Estimates for ACST - MarketWatch CNBC View the Earnings History for ACST - CNBC
StockMarketWatch View the ACST Earnings - StockMarketWatch MacroAxis View ACST Buy or Sell Recommendations - MacroAxis
Bullish View the ACST Bullish Patterns - American Bulls Short Pains View ACST Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACST Stock Mentions - StockTwits PennyStocks View ACST Stock Mentions - PennyStockTweets
Twitter View ACST Stock Mentions - Twitter Invest Hub View ACST Investment Forum News - Investor Hub
Yahoo View ACST Stock Mentions - Yahoo! Message Board Seeking Alpha View ACST Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACST - SECform4.com Insider Cow View Insider Transactions for ACST - Insider Cow
CNBC View ACST Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACST - OTC Markets
Yahoo View Insider Transactions for ACST - Yahoo! Finance NASDAQ View Institutional Holdings for ACST - NASDAQ


Stock Charts

FinViz View ACST Stock Insight & Charts - FinViz.com StockCharts View ACST Investment Charts - StockCharts.com
BarChart View ACST Stock Overview & Charts - BarChart Trading View View ACST User Generated Charts - Trading View




Latest Financial News for ACST


Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
Posted on Monday April 15, 2019

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s two on-going Phase 3 TRILOGY trials (TRILOGY 1 and TRILOGY 2) have exceeded a combined 89% patient randomization, and more than 40% of the patients in both trials have completed their 6-month treatment plan. With the expected approximate 1 month of data clean-up following the “last patient out”, topline results for TRILOGY 1 are expected in December. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “We are very pleased to announce that our two TRILOGY Phase 3 trials are proceeding well and according to plan.


Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
Posted on Monday April 01, 2019

Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal LAVAL, Québec,.


Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
Posted on Tuesday March 26, 2019

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company’s President and CEO, Jan D’Alvise, is scheduled to present at the 2019 Spring Investor Summit on Tuesday, April 2, 2019 at 1:30 pm Eastern Time at The Essex House in New York City. The Spring Investor Summit will take place in New York City at the Essex House on April 1st and 2nd.


Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
Posted on Wednesday March 13, 2019

Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.